Literature DB >> 6478571

Preservation of high-energy phosphates by verapamil in reperfused myocardium.

R Lange, J Ingwall, S L Hale, K J Alker, E Braunwald, R A Kloner.   

Abstract

To determine whether verapamil prevents depletion of adenine nucleotides during and after severe myocardial ischemia, dogs were subjected to 15 min occlusions of the left anterior descending coronary artery followed by 240 min of reperfusion. One hour before occlusion, dogs were randomly assigned to a treatment group (n = 10) to which an infusion of intravenous verapamil was given until the onset of reperfusion or to an untreated saline group (n = 9). Verapamil reduced mean aortic pressure and heart rate. After 15 min of ischemia, endocardial adenosine triphosphate (ATP) level, determined by needle biopsy, decreased in the untreated group from 34.7 +/- 2.0 to 24.4 +/- 2.7 nmol X mg protein-1 (p less than .005 vs preocclusion) and in the verapamil group from 32.8 +/- 1.5 to 30.3 +/- 1.5 nmol X mg protein-1 (NS vs preocclusion). Dogs receiving verapamil had significantly higher ATP levels than untreated animals after 90 and 240 min of reperfusion. In untreated animals the sum of inosine and hypoxanthine levels increased during occlusion from very low levels to 4.6 +/- 1.1 nmol X mg protein-1 in the epicardium and to 6.8 +/- 1.5 nmol X mg protein-1 in the endocardium (p less than .05 compared with preocclusion values). In verapamil-treated dogs inosine and hypoxanthine levels increased to only 1.2 +/- 0.3 (epicardium) and 1.9 +/- 0.6 nmol X mg protein-1 (endocardium) (both NS compared with preocclusion values). After 90 min of reperfusion the sum of ATP, adenosine diphosphate, adenosine monophosphate, inosine, and hypoxanthine levels was decreased in the endocardium by 10.2 nmol X mg protein-1 in the untreated group, but no change was observed in verapamil-treated animals. We conclude that breakdown of ATP to inosine and hypoxanthine during severe ischemia is reduced by verapamil, resulting in higher ATP concentrations during occlusion and reperfusion and decreased washout of the diffusible purines inosine and hypoxanthine during reperfusion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6478571     DOI: 10.1161/01.cir.70.4.734

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  JTV-519, a novel cardioprotective agent, improves the contractile recovery after ischaemia-reperfusion in coronary perfused guinea-pig ventricular muscles.

Authors:  K Ito; S Shigematsu; T Sato; T Abe; Y Li; M Arita
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia.

Authors:  Q Timour; B Bui-Xuan; G Faucon; J F Aupetit
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

3.  Should we still administer calcium during cardiopulmonary resuscitation?

Authors:  J L Vincent
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

Review 4.  Basic mechanisms involved in the protection of the ischaemic myocardium. The role of calcium antagonists.

Authors:  W G Nayler
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  Protective effects of calcium antagonists against ischaemia and reperfusion damage.

Authors:  R Ferrari; O Visioli
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 6.  Metabolic regulation of in vivo myocardial contractile function: multiparameter analysis.

Authors:  M D Osbakken
Journal:  Mol Cell Biochem       Date:  1994 Apr-May       Impact factor: 3.396

Review 7.  Calcium antagonists and stunned myocardium: importance for clinicians?

Authors:  K Przyklenk; R A Kloner
Journal:  Cardiovasc Drugs Ther       Date:  1991-10       Impact factor: 3.727

8.  Verapamil-potassium cardioplegia: a two-year experience with 470 patients.

Authors:  G L Hicks
Journal:  Tex Heart Inst J       Date:  1986-03

9.  Limitation of myocardial necrosis with verapamil during sustained coronary occlusion in the closed-chest dog.

Authors:  J G Kingma; D M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

10.  Beneficial effects of verapamil during metabolic acidosis in isolated perfused rat hearts.

Authors:  W Markiewicz; S S Wu; R Sievers; W W Parmley; T A Watters; T L James; C B Higgins; J Wikman-Coffelt
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.